SecBot SecBot
8-K ·Filed Aug 5, 2026

ELAN

Elanco Animal Health Inc
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001739104-26-000040
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The second consecutive beat-and-raise quarter with accelerating innovation adoption and faster deleveraging supports a re-rating. Watch for Q3 guidance of $1.195B-$1.220B revenue and $0.19-$0.22 adjusted EPS, which implies a seasonal step-down but still strong YoY growth. The path to below 3x net leverage by year-end 2027 is a key catalyst for capital allocation flexibility.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$26.22
T+0 close · Aug 5, 2026 · via day close
Latest settled
−11.37%
T+60 · $23.24
Vs SPY
−11.31%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 5 $26.22entry
  2. T+1 · 3mo ago −7.70%α −7.54% · $24.20
  3. T+5 · 3mo ago −15.95%α −16.30% · $22.04
  4. T+20 · 3mo ago −5.87%α −5.27% · $24.68
  5. T+60 · 19d ago −11.37%α −11.31% · $23.24
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Elanco reported Q2 2026 adjusted EPS of $0.34, a 26.5% beat vs. the $0.27 consensus, on revenue of $1.368B (8% organic constant currency growth). The company raised full-year guidance across all key metrics, revenue to $5.09B-$5.14B, adjusted EBITDA to $1.01B-$1.035B, and adjusted EPS to $1.10-$1.16, while improving its year-end net leverage target to ~3.0x. This marks a second consecutive beat-and-raise quarter, driven by accelerating innovation product adoption (Zenrelia, Credelio Quattro) and faster-than-expected margin expansion from the Elanco Ascend productivity program.

Key Financial Metrics

EPS
$0.34
est $0.27 · +25.9%
Revenue
$1.4B
est $1.3B · +4.4% · +10.0% YoY
Rating
strong beat
Guidance
$5.09B-$5.14B
raised
Gross Margin
58.3%

Key Facts

  • Q2 2026 revenue of $1,368M, +10% reported YoY, +8% organic constant currency
  • Adjusted EPS of $0.34 beat consensus of $0.27 by 26.5%
  • Full-year 2026 guidance raised: revenue to $5.09B-$5.14B, adjusted EBITDA to $1.01B-$1.035B, adjusted EPS to $1.10-$1.16
  • Net leverage ratio improved to 3.1x at quarter-end, down from 3.5x at Q1 end and 3.6x at Dec 2025
  • Innovation revenue target raised to $1.25B; Zenrelia achieved blockbuster status, Credelio Quattro penetrated >50% of U.S. clinic base
  • Operating cash flow of $277M in Q2 vs $237M in prior year; adjusted gross margin expanded 80bps to 58.1%

Financial Impact

Q2 revenue $1.368B, adjusted EPS $0.34; full-year guidance raised by ~$70M at midpoint on revenue and ~$0.07 on adjusted EPS

revenueepsebitdadebt leveragegross margin

Risk Factors

  • Q3 guidance implies a sequential revenue decline of ~11% from Q2, reflecting normal seasonality in animal health
  • Operating expenses up ~10% YoY in constant currency for Q3, pressuring near-term margins
  • Swine revenue declined 4% YoY on an organic constant currency basis, a potential headwind if pork demand softens
  • Integration of AHV International acquisition adds execution risk
  • Substantial debt load ($3.16B net debt) limits financial flexibility despite deleveraging progress

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001739104-26-000040
Document: elan-20260805.htm0001739104-26-000040
Document: 0001739104-26-000040-index-headers.html0001739104-26-000040
Document: 0001739104-26-000040-index.html0001739104-26-000040
Document: 0001739104-26-000040.txt0001739104-26-000040
8-K Data (Synthetic)0001739104-26-000040

Track record

19 reports on ELAN

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +15.03% at T+5 after the May 19, 2026 report. 9 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $26.68 Now $26.41 −1.01% settles Feb 12
  2. Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $26.78 Now $26.41 −1.38% settles Feb 11
  3. Nov 6, 202610d ago 8-K Bullish 6/10 Entry $25.74 Now $26.41 +2.60% settles Feb 4
  4. Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $23.68 Now $26.41 +11.53% settles Feb 3
  5. Nov 3, 202613d ago 3 Neutral 1/10 Entry $25.31 Now $26.41 +4.35% settles Feb 2
  6. Oct 14, 20264w ago Institutional Cluster Bullish 4/10 Entry $23.54 Now $26.41 +12.19% settles Jan 12
  7. Sep 11, 20269w ago Press Release Neutral 1/10 Entry $23.17 Now $26.41 +13.98% settles Dec 7
  8. Aug 21, 202612w ago Insider Cluster Bullish 6/10 Entry $24.42 Now $26.41 +8.15% settles Nov 17
  9. Aug 21, 202612w ago Insider Cluster Bullish 4/10 Entry $24.42 Now $26.41 +8.15% settles Nov 17
  10. Aug 18, 202612w ago Insider Cluster Bullish 4/10 Entry $24.50 to $26.50 Now $26.41 +7.80% ▲ +8.16% +9.72% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 5h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 5, 2026